EYPT Overview

EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

Wall Street analysts forecast EYPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EYPT is31.50 USD with a low forecast of 20.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

EyePoint Inc revenue for the last quarter amounts to 696.00K USD, decreased -97.15

EyePoint Inc. EPS for the last quarter amounts to -0.99 USD, increased 52.31

EyePoint Inc (EYPT) has 214 emplpoyees as of May 31 2026.

Today EYPT has the market capitalization of 1.14B USD.